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Seasonal inﬂuenza viruses cause annual disease epidemics that affect individuals at low and high risk for
secondary illnesses. Inﬂuenza vaccines are widely used in high-risk patients to prevent infection, but the
protection afforded varies by population; uptake is also limited in some groups. Antiviral drugs for inﬂuenza
are now readily available. Oseltamivir is the most widely used antiviral for the treatment and prophylaxis of sea-
sonal inﬂuenza, and its efﬁcacy and safety are now well established in a variety of populations. In addition to
decreasing the severity and duration of the symptoms of inﬂuenza, clinical and epidemiological studies demon-
strate that oseltamivir signiﬁcantly reduces the frequency of secondary illnesses and exacerbation of underlying
conditions; survival is also signiﬁcantly improved in seriously ill patients who are hospitalized with severe inﬂu-
enza. Resistant viruses are isolated with a low frequency during oseltamivir treatment (0.33% in adults and
4.0% in children among almost 2000 oseltamivir-treated patients enrolled onto Roche-sponsored clinical trials
of oseltamivir treatment during the oseltamivir development programme). However, an oseltamivir-resistant
inﬂuenza A (H1N1) virus emerged in Europe during the 2007–08 season and circulated in the southern and
northern hemispheres in 2008–09. No link with oseltamivir usage could be detected, and the clinical impact
of these viruses was limited. Oseltamivir-susceptible pandemic (H1N1) 2009 viruses now predominate in
many countries. Oseltamivir is generally well tolerated, with a similar adverse event proﬁle to placebo.
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Introduction
Seasonal inﬂuenza viruses continue to impose a substantial
disease burden on individuals at low and high risk for secondary
illnesses. In the USA, the CDC estimates that between 5% and
20% of the population may become infected during each inﬂu-
enza season,
1 and similar rates have been reported in Europe
and Asia.
2,3 As a result of seasonal inﬂuenza, 36000 deaths
and 226000 hospitalizations are estimated to occur in the USA
each year, the majority of which involve the very young
(,2 years), the elderly ( 65 years) and those with co-morbid
conditions, such as chronic pulmonary, cardiovascular and meta-
bolic disorders.
4,5 These patients are considered at high risk for
inﬂuenza-associated complications, which may include sinusitis,
pharyngitis, bronchitis, pneumonia, croup and otitis media.
5
Lower risk populations are also susceptible to inﬂuenza and its
complications, and these patients may be responsible for a size-
able proportion of the societal and healthcare costs associated
with the disease.
6–8
It is widely accepted that vaccination is the most effective
way of minimizing the disease burden of inﬂuenza.
4 When well
matched to circulating strains, inactivated and live attenuated
inﬂuenza vaccines provide between 80% and 100% protection
against infection.
9 However, the protection afforded is known
to be inﬂuenced by patient characteristics, with the very
young, the frail elderly and those with co-morbid conditions
often deriving only limited beneﬁt.
9 Efﬁcacy is also compromised
when the circulating viruses are a poor match for those included
in the vaccine.
4 Vaccination programmes may also be poorly
established or of limited scope in some countries,
10 while in
those with more comprehensive policies uptake can be subopti-
mal in deﬁned patient groups.
11,12 For these reasons, large
numbers of patients who are at risk for the potentially serious
complications of inﬂuenza continue to be susceptible to infec-
tion. As such, there is a pressing need for effective treatment
options.
In the USA, the CDC recommends the antiviral neuraminidase
inhibitors oseltamivir and zanamivir (rather than amantadine or
rimantadine from the older adamantane class) for the treatment
of seasonal inﬂuenza in individuals presenting to medical care
with symptoms of ,48 h duration (Table 1).
4 Although not con-
sidered a substitute for vaccination, antiviral prophylaxis is also
recommended for high-risk individuals and other patient
groups when the risk of infection is high (Table 1). These
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ii11recommendations are generally reﬂected in the most recent
advice on antiviral use from the Infectious Diseases Society of
America (IDSA)
13 and in European national guidelines, although
no pan-European recommendations currently exist.
14 Of the two
neuraminidase inhibitors, oseltamivir has been most widely used
in clinical practice, with .65 million treatment courses pre-
scribed worldwide (Roche, data on ﬁle).
Oseltamivir treatment in seasonal inﬂuenza
Clinical trials in low- and high-risk groups
The efﬁcacy of oseltamivir in the treatment of inﬂuenza has been
widely evaluated in randomized, controlled studies involving chil-
dren  1 year and adults of all ages. In the pivotal trials of
oseltamivir in low-risk adolescents and adults aged  13 years,
patients with inﬂuenza-like illness were randomized to twice-
daily treatment with 75 or 150 mg of oseltamivir or
placebo.
15,16 Compared with placebo, oseltamivir signiﬁcantly
reduced the duration of illness by 25%–32% (P 0.05) and the
severity of symptoms by 18%–38% (P,0.02) in patients with
laboratory-conﬁrmed inﬂuenza (n¼374 and 475, respect-
ively).
15,16A subsequent investigation demonstrated a signiﬁcant
correlation (P,0.0001) between the duration of illness and the
time of oseltamivir initiation, such that commencement within
12 h of symptom onset reduced illness duration by 3.1 days
more than initiation at 48 h (illness duration: 108 h versus
182.6 h).
17 In the study described by Treanor et al.,
16 the inci-
dence of physician-diagnosed secondary complications was
signiﬁcantly reduced in the active treatment group (P¼0.03
versus placebo), as was the frequency of antibiotic usage. In a
pooled analysis of 10 clinical trials involving 2413 patients
(13–97 years) with inﬂuenza-like illness who received 75 mg of
oseltamivir or placebo twice daily, active treatment signiﬁcantly
reduced the incidence of inﬂuenza-related lower respiratory tract
complications requiring antibiotics by 55% (P,0.001 versus
placebo). The incidence of such complications in high-risk
patients was also signiﬁcantly reduced (P¼0.02, Table 2).
18
Anumberofclinicalstudieshaveexploredtheuseofoseltamivir
treatment in children. In one trial, children aged 1212 years with
inﬂuenza-like illness of ,48 h received twice-daily oseltamivir
(2 mg/kg)orplacebofor5 days.
19 Comparedwithplacebo,oselta-
mivir signiﬁcantly reduced symptom duration in those with
laboratory-conﬁrmed inﬂuenza (n¼452) by 36 h (P,0.0001),
and the extent and severity of illness by 29% (P¼0.002).
Reductions were also seen in the incidence of complications,
especially otitis media (44% reduction versus placebo), and anti-
biotic prescriptions were signiﬁcantly less frequent (31% versus
41% on placebo; P¼0.03).
19 Using the same treatment regimen,
Johnston et al.
20 randomized asthmatic children aged 6–
12 years with inﬂuenza-like illness to oseltamivir or placebo. Osel-
tamivir treatment led to a reduction in illness duration for those
with laboratory-conﬁrmed inﬂuenza (n¼179) of 10.4 h (8%),
although this was not signiﬁcant (P¼0.5420 versus placebo).
However,signiﬁcantbeneﬁtswereobservedintermsofpulmonary
function(improvementinforcedexpiratoryvolumeat1 sof10.8%
versus 4.7% with placebo; P,0.02) and asthma exacerbations up
to day 7 (68% versus 51% of patients remained within 20% of the
highestpeak ﬂowrate;P¼0.03; Table 2).
20 Off-label use of oselta-
mivir in infants ,1 year has also been evaluated. Tamura et al.
21
compared outcomes in infants ,1 year (n¼47) with those in
older children (1–15 years) with inﬂuenza, who either received
5 days of oseltamivir treatment started within 48 h of symptom
onset (n¼486) or did not (n¼95). The duration of fever in the
oseltamivir-treated infant group (2.7+1.7 days) was similar to
that in the older group who received oseltamivir (2.5+2.1 days),
and signiﬁcantly shorter than that in the untreated group
(4.2+3.8 days; P,0.0001). Further data in German infants also
indicate that oseltamivir treatment may be efﬁcacious in this
population.
22
Several clinical investigations have examined the beneﬁt of
oseltamivir treatment in high-risk patient groups. A pooled analy-
sis of data from the oseltamivir clinical trial programme revealed
that oseltamivir treatment signiﬁcantly reduced the duration of
illness among patients with chronic cardiac diseases by 32%
versus placebo (P,0.05) and by 30% in those with respiratory
disease (P,0.01 versus placebo).
23 Data from individual studies
are presented in Table 2. Lin et al.
24 explored the efﬁcacy of osel-
tamivir in Chinese patients with chronic respiratory or cardiac dis-
eases. Patients with inﬂuenza-like illness received 75 mg of
oseltamivir twice daily for 5 days or symptomatic therapy. In
patients with laboratory-conﬁrmed inﬂuenza (n¼56), oseltamivir
signiﬁcantly reduced illness duration (by 36.8%) and severity (by
43.1%) versus symptomatic therapy (P¼0.0479 and P¼0.0002,
respectively). The incidence of complications and antibiotic use
was also signiﬁcantly reduced (P¼0.0053 and P¼0.0167 versus
symptomatic therapy, respectively).
In a prospective cohort study, McGeer et al.
25 assessed the
impact of antiviral therapy on the outcomes of patients hospital-
ized with severe inﬂuenza in southern Ontario, Canada. In their
Table 1. CDC recommendations for the use of neuraminidase inhibitors
in seasonal inﬂuenza
4
Treatment of laboratory-conﬁrmed
inﬂuenza (commencing within 48 h
of symptom onset)
Prophylaxis during periods of
increased inﬂuenza activity
† hospitalized patients (even if
started after 48 h)
† individuals with conﬁrmed
inﬂuenza pneumonia
† persons with bacterial co-infection
† individuals at high risk of
inﬂuenza-related complications
† low-risk individuals who want to
decrease the duration and severity
of their symptoms and limit their
chances of transmitting inﬂuenza
to others at high risk of
complications
† persons at high risk during the
2 weeks after inﬂuenza
vaccination
† individuals for whom inﬂuenza
vaccination is contraindicated
† family members or healthcare
providers who are likely to be
exposed to people at high risk,
unvaccinated individuals or
infants aged ,6 months
† high-risk individuals, their
close contacts and healthcare
workers when vaccines are
poorly matched to circulating
strains
† healthcare providers involved
in a response to an
institutional inﬂuenza
outbreak involving residents at
high risk (e.g. nursing home)
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ii12Table 2. Effect of treatment with oseltamivir on complications of inﬂuenza in high-risk patients
Outcome in patients with laboratory-conﬁrmed inﬂuenza
Study Treatment regimen Population (number of patients analysed) outcome incidence P value
Kaiser
et al.
18
2003
75 mg of oseltamivir twice
daily versus placebo
high-risk adolescents and adults (n¼769) lower respiratory
tract
complications
12.2% with oseltamivir versus 18.5% with placebo 0.02
Johnston
et al.
20
2005
2 mg/kg oseltamivir twice
daily versus placebo
children aged 6–12 years with asthma
(n¼179)
improvement in
pulmonary
function
10.8% with oseltamivir versus 4.7% with placebo 0.0148
asthma
exacerbations
68% of oseltamivir recipients within 20% of peak
ﬂow versus 51% with placebo
0.031
Lin et al.
24
2006
75 mg of oseltamivir twice
daily versus
symptomatic therapy
adolescents and adults with cardiac or
respiratory diseases (n¼56)
complications 11% with oseltamivir versus 45% with control 0.0053
antibiotics 37% with oseltamivir versus 69% with control 0.0167
Lee et al.
27
2009
75 mg of oseltamivir twice
daily versus no antiviral
hospitalized adults aged .16 years with
inﬂuenza (n¼147)
viral shedding 10.2% culture positive at  4 days post-symptoms
with oseltamivir versus 38.5% with no antiviral;
culture positive at  5 days: 4.2% versus 21.2%
0.002 ( 4 days);
0.006 ( 5d a y s )
McGeer
et al.
25
2007
75 mg of oseltamivir twice
daily versus no antiviral
hospitalized adults with inﬂuenza
(n¼327)
mortality odds ratio with oseltamivir versus no antiviral: 0.21
(95% CI 0.06–0.80)
0.02
hospitalized adults aged  65 years with
inﬂuenza (n¼227)
mortality odds ratio with oseltamivir versus no antiviral: 0.24
(95% CI 0.06–0.92)
not reported
Chemaly
et al.
29
2006
75 mg of oseltamivir twice
daily versus no antiviral
immunocompromised stem cell
transplant recipients aged  1 year
with inﬂuenza A (n¼72)
pneumonia 12% with oseltamivir versus 48% with no antiviral ,0.05
mortality 0% with oseltamivir versus 38% with no antiviral 0.001
CI, conﬁdence interval.
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A
Cstudy, 327 adults admitted to Toronto Invasive Bacterial Diseases
Network (TIBDN) hospitals with laboratory-conﬁrmed inﬂuenza
were enrolled between 1 January 2005 and 31 May 2006. Of
these, 103 patients received oseltamivir. Compared with those
who did not receive antivirals, oseltamivir treatment was associ-
ated with a signiﬁcant reduction in 15 daymortality in all patients
fodds ratio (OR) 0.21 [95% conﬁdence interval (CI) 0.06–0.80];
P¼0.02g and in those aged  65 years [OR 0.24 (95% CI 0.06–
0.92)].
25Inasecondsurveillancestudybythesamegroup,oselta-
mivir treatment was shownto bea signiﬁcantpredictorofsurvival
in patients with laboratory-conﬁrmed inﬂuenza who were
admitted to intensive care units within the TIBDN [OR 3.2 (95%
CI 1.5–7.0)].
26 In a 1 year, prospective, observational study, Lee
et al.
27 evaluated viral loads and factors affecting viral clearance
in 147 persons hospitalized with severe inﬂuenza A (H3N2). Osel-
tamivir treatment started on or before symptom day 4 was inde-
pendently associated with an accelerated decrease in viral RNA
concentration and viral RNA clearance at 1 week. The same
group also conducted a prospective, observational study in two
general hospitals in Hong Kong during 2007 and 2008.
28 All par-
ticipants were inpatients aged  18 years and had laboratory-
conﬁrmed inﬂuenza. In total, 760 patients were studied, and
most were of older age (mean 70 years), had underlying medical
conditions (60%) and were hospitalized with complications
(78%). Of these, 395 (52%) were treated with oseltamivir
(77.7%within2 daysofsymptomonset).Antiviralusewasassoci-
ated with reduced in-hospital mortality (3.8% versus 6.0% for
patients on no antiviral), when adjusted for time to presentation
and complications.
28
A number of uncontrolled studies have also investigated the
use of oseltamivir in immunocompromised patients. In a retro-
spective study in adults with haematological malignancies who
had undergone haematopoietic stem cell transplantation
(HSCT), the incidence of pneumonia was signiﬁcantly lower in 72
patients infected with inﬂuenza A treated with oseltamivir (12%
versus 48%; P,0.05 versus no antiviral).
29 A similar ﬁnding was
observed in patients infected with inﬂuenza B, and no patient
whoreceivedneuraminidaseinhibitortherapydiedfrominﬂuenza,
compared with three of eight (38%) patients who did not
(P¼0.001). Further studies in HSCT patients have conﬁrmed the
efﬁcacy of oseltamivir in preventing illness progression and
death,
30,31andpositiveoutcomeshavealsobeennotedinleukae-
mia
32 and bone marrow transplant patients.
33
Epidemiological studies in low- and high-risk groups
The efﬁcacy of oseltamivir in treating inﬂuenza and preventing its
complications has been analysed using epidemiological data col-
lected through various US health insurance databases (Table 3).
One such investigation used the MarketScan Health Insurance
Claims Database to evaluate the incidence of inﬂuenza-
associated complications in children, adolescents and adults
during the 2000–05 inﬂuenza seasons.
34 Claims outcomes
were collected for inﬂuenza patients who received oseltamivir
and compared with a matched control group who did not
receive antivirals (n¼31674 per group). Compared with the
no-antiviral group, signiﬁcant reductions were detected with
oseltamivir for the risk of developing secondary pneumonia
(15%), respiratory illnesses (20%) and otitis media and its com-
plications (31%). Oseltamivir was also associated with signiﬁcant
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ii14Peters et al.
34 2008 MarketScan, 2000–05 seasons children, adolescents and adults
(n¼31674; 31674)
pneumonia RR 0.85 (0.73–0.98) 15%
respiratory illnesses RR 0.80 (0.76–0.83) 20%
otitis media RR 0.69 (0.61–0.79) 31%
hospitalization RR 0.62 (0.52–0.74) 38%
hospitalization due to
respiratory illness
RR 0.43 (0.27–0.69) 57%
children aged  12 years (n¼7772; 7389) pneumonia RR 0.47 (0.33–0.66) 53%
respiratory illnesses RR 0.72 (0.65–0.80) 28%
otitis media RR 0.61 (0.54–0.71) 39%
hospitalization RR 0.50 (0.31–0.81) 50%
hospitalization due to
respiratory illness
RR 0.09 (0.01–0.70) 91%
children aged 1–2 years (n¼1303; 1379) pneumonia RR 0.48 (0.24–0.99) 52%
respiratory illnesses RR 0.69 (0.54–0.87) 31%
otitis media RR 0.68 (0.52–0.88) 32%
children aged 3–5 years (n¼1820; 1961) respiratory illnesses RR 0.74 (0.59–0.92) 26%
otitis media RR 0.71 (0.53–0.95) 29%
children aged 6–12 years (n¼4649;
4049)
pneumonia RR 0.43 (0.26–0.71) 57%
respiratory illnesses RR 0.80 (0.75–0.85) 20%
otitis media RR 0.71 (0.54–0.95) 29%
Blumentals and
Schulman
35 2007
MarketScan, 2000–06 seasons adolescents aged  13 years and adults
(n¼36751; 36751)
respiratory diseases HR 0.82 (0.79–0.86) 18%
otitis media HR 0.77 (0.65–0.93) 23%
hospitalization HR 0.78 (0.67–0.91) 22%
Orzeck et al.
42 2007 MarketScan, 2000–06 seasons high-risk adults aged  18 years with
diabetes (n¼2919; 6171)
respiratory illnesses RR 0.83 (0.73–0.93) 17%
hospitalization RR 0.70 (0.52–0.94) 30%
Piedra et al.
39 2009 MarketScan, 2000–06 seasons high-risk children with underlying medical
conditions (n¼1634; 3721)
respiratory illnesses
other than
pneumonia
14 day HR 0.74 (0.63–0.8) 26%
30 day HR 0.87 (0.77–0.97) 13%
otitis media and its
complications
14 day HR 0.69 (0.48–0.99) 31%
30 day HR 0.70 (0.53–0.92) 30%
all-cause
hospitalization
14 day HR 0.33 (0.13–0.83) 67%
30 day HR 0.49 (0.27–0.89) 51%
Majid et al.
40 2009 Insurance database, May
2000–September 2006
adults aged  18 years (n¼49238;
102692)
stroke or transient
ischaemic heart
attack
HR 0.72 (0.62–0.82) 28%
Casscells et al.
41
2009
TRICARE military patient database,
October 2003–September 2007
high-risk adults aged  18 years with a
history of cardiovascular disease
(n¼6784; 30698)
recurrent
cardiovascular
events
OR 0.417 (0.349–0.498) 60%
RR, relative risk; HR, hazard ratio; OR, odds ratio.
aDifferences between the oseltamivir and control groups were considered statistically signiﬁcant if the 95% conﬁdence interval did not include 1.
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A
Cdecreases in the risk of hospitalization for any reason (38%) and,
in particular, due to respiratory illnesses (57%). Parallel outcomes
were noted using the same database in analyses of adults and
adolescents aged  13 years,
35 and children aged 1–12 years;
a signiﬁcant reduction in antibiotic usage was also noted.
36
Data from other health claims sources also indicate that oselta-
mivir treatment is associated with signiﬁcantly reduced inci-
dences of pneumonia, hospitalization and other complications,
and antibiotic use (Table 3).
37,38 In children with underlying
medical conditions registered on the MarketScan database, osel-
tamivir was associated with signiﬁcant reductions in the risks of
respiratory illnesses other than pneumonia, otitis media and its
complications, and all-cause hospitalization in the 14 and
30 day periods after inﬂuenza diagnosis.
39
Medical and pharmaceutical claims data recorded between
May 2000 and September 2006 have also been used to compare
the incidence of stroke or transient ischaemic attack (TIA) in the
6 months after inﬂuenza diagnosis in patients  18 years pre-
scribed either oseltamivir (n¼49238) or no antiviral treatment
(n¼102692).
40 Oseltamivir treatment was associated with a
28% reduction in risk of stroke or TIA [hazard ratio 0.72 (95% CI
0.6220.82)]. Signiﬁcant reductions in risk were also detected
within 1 and 3 months of the diagnosis and in patients aged
,65 years (34% reduction within 6 months) and  65 years
(51% reduction within 1 month). A more recent database study
examined 37482 military health system beneﬁciaries aged
 18 years witha historyofcardiovascular(CV)diseaseand asub-
sequentdiagnosisofinﬂuenzafrom1October2003to30Septem-
ber 2007.
41 Subjects were grouped according to whether or not
theyhadreceivedoseltamivirwithin2 daysoftheirinﬂuenzadiag-
nosis. The incidence of recurrent CVevents within 30 days of inﬂu-
enza diagnosis was signiﬁcantly loweramong oseltamivir-treated
subjects than those who did not receive oseltamivir (8.5% versus
21.2%; P,0.005). Using a propensity-scored logistic regression
model, a statistically signiﬁcant reduction in CV events with
oseltamivir treatment was found [OR 0.417 (95% CI 0.349–
0.498)]. In a study of the MarketScan database, claims data
from the 2000–06 inﬂuenza seasons were screened to assess
the inﬂuence of oseltamivir on the risk of complications in adults
 18 years with diabetes.
42 Compared with no antiviral therapy
(n¼6171), patients on oseltamivir (n¼2919) had a signiﬁcantly
reduced risk of respiratory illnesses (17% reduction) or hospitaliz-
ation for any illness (30% reduction) (Table 3).
Prophylaxis with oseltamivir in seasonal
inﬂuenza
Oseltamivir post-exposure prophylaxis (PEP) in
households
The efﬁcacy of oseltamivir as PEP in households has been exam-
ined in two randomized controlled trials involving both low- and
high-risk subjects. Following a successful randomized trial invol-
ving individuals aged  12 years within households in North
America and Europe,
43 a second household study including
children  1 year as well as adults and elderly subjects was
undertaken.
44 Index cases (n¼298) started oseltamivir treat-
ment following the onset of inﬂuenza-like illness, and household
contacts were randomized by household to once-daily oseltami-
vir PEP for 10 days (n¼410) or twice-daily oseltamivir treatment
for 5 days on the emergence of inﬂuenza-like illness in the
individual (n¼402, of whom 52 received treatment) at rec-
ommended doses. Excluding participants with laboratory-
conﬁrmed inﬂuenza at study start, 228 contacts in the PEP
group and 248 contacts in the treatment group were exposed
to 184 index cases with laboratory-conﬁrmed inﬂuenza. Com-
pared with the treatment-only arm, the protective efﬁcacy of
oseltamivir PEP against laboratory-conﬁrmed inﬂuenza was
84.5% for individual contacts (P¼0.002; Figure 1) and 78.8%
for households (P¼0.0008).
44 The incidence of laboratory-
conﬁrmed inﬂuenza in paediatric contacts aged 1212 years
(n¼117) was analysed separately and was reduced by 80.1%
in the PEP group compared with the treatment-only group (4%
versus 21%, respectively; P¼0.0206; Figure 1).
Oseltamivir seasonal prophylaxis
In two studies of identical design, the efﬁcacy of inﬂuenza pro-
phylaxis with oseltamivir in low-risk adults (aged 18265 years)
in the USA during the 1997–98 inﬂuenza season was explored.
45
Subjects were randomly assigned to 75 mg of oseltamivir (taken
once or twice daily; n¼520 for both groups) or placebo (n¼519)
for 42 days (6 weeks). Due to a low incidence of laboratory-
conﬁrmed inﬂuenza in both studies, the studies were pooled to
provide sufﬁcient power to evaluate efﬁcacy. The proportion of
subjects with laboratory-conﬁrmed inﬂuenza was signiﬁcantly
lower in each of the oseltamivir groups than in the placebo
group (1.2% and 1.3% versus 4.8%; P,0.001 and P¼0.001,
respectively). Protective efﬁcacy with oseltamivir was 76% in
the once-daily arm and 72% in the twice-daily arm. In another
study, the protective efﬁcacy of oseltamivir prophylaxis among
frail elderly individuals (aged  65 years) in nursing homes
during the 1998–99 northern hemisphere season was con-
sidered.
46 Participants received 75 mg of oseltamivir or placebo
once daily for 6 weeks, and were vaccinated against inﬂuenza
in accordance with care home policy. In total, 548 residents
were enrolled, of whom 80% were vaccinated. The incidence of
laboratory-conﬁrmed clinical inﬂuenza was signiﬁcantly lower
in those randomly assigned to oseltamivir (n¼276) than the
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Figure 1. Incidence of laboratory-conﬁrmed inﬂuenza infection in
household contacts without inﬂuenza at baseline who did or did not
receive oseltamivir post-exposure prophylaxis (commenced within 48 h
of symptom onset). Figure derived from data in Hayden et al.
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ii16272 subjects on placebo (0.4% versus 4.4%, respectively;
P¼0.002), a reduction of 92% (Figure 2).
46 Oseltamivir prophy-
laxis provided a similar protective efﬁcacy whether subjects
had been vaccinated or not. The protective efﬁcacy of oseltamivir
prophylaxis was a secondary endpoint in an open-label study
involving children 1212 years.
47 Weight-based unit doses (30–
75 mg) of oseltamivir were taken once daily for 42 consecutive
days (6 weeks). Although not powered to determine efﬁcacy,
no cases of laboratory-conﬁrmed inﬂuenza were recorded in
the 49 children who received oseltamivir.
A randomized, double-blind, placebo-controlled study of osel-
tamivir prophylaxis has recently been conducted in immunocom-
promised patients. In this trial, adults and children receiving solid
organ (liver and/or kidney) or allogeneic HSCTs (n¼470) received
12 weeks of oseltamivir or placebo.
48 The primary endpoint was
the proportion of subjects with clinical inﬂuenza and positive
viral culture and/or a  4-fold rise in antibody titre from baseline.
Safety and tolerability and the incidence of resistant virus were
also assessed. Data presented from this trial suggest that
although the primary study endpoint was not met, active treat-
ment was associated with a signiﬁcant reduction in the incidence
of laboratory-conﬁrmed inﬂuenza by RT–PCR or viral culture. Osel-
tamivir was well tolerated and no resistant virus was detected.
Resistance to oseltamivir among seasonal
inﬂuenza viruses
Resistance in the clinical trial programme
Inthe3 yearspriortotheintroductionofoseltamivir(1996–99),no
inﬂuenza viruses with reduced susceptibility to oseltamivir were
detectedinglobalsurveillancebytheNeuraminidaseInhibitorSus-
ceptibility Network (NISN).
49 Pooled data from almost 2000
oseltamivir-treated patients during the oseltamivir clinical treat-
ment programme showed that drug-induced resistance occurred
with a low incidence (0.33% in adults and 4.0% in children)
(Table 4).
50 The higher level of resistance among children was
linked to the 2 mg/kg ﬂat dose employed in the paediatric
studies, which led to the formulation of a weight-based unit
dosing schedule for children. No resistance was detected in any of
theprophylaxisstudiesinadultsandchildren.Resistancemutations
werefoundininﬂuenzaAvirusesonlyandwerespeciﬁctovirussub-
types; the most frequent mutations in N2 viruses were R292K and
E119V, whereas the most frequent in N1 viruses was H275Y
(often referred to as H274Y, which accords to N2 numbering).
50
In clinical trials, oseltamivir-resistant virus occurred only tran-
siently in viral samples shed by patients,
51,52 emerging on study
days 4 or 6 and clearing by day 8 in adults and day 10 in chil-
dren.
50 In one study,
53 resistant viruses were detected in 2 of
54 oseltamivir-treated adults inoculated with H1N1. In both
patients, the onset of resistance was associated with a transient
spike in viral shedding that subsided by day 7. No differences
were seen between the clinical signs and disease course of
patients carrying resistant viruses and of those carrying wild-
type virus.
19,54 Animal models used to characterize some of
the resistant virus strains isolated during the clinical trial pro-
gramme found that all of these isolates were less ﬁt than wild-
type strains in some way.
55–60 In particular, the H275Y mutant
not only showed poorer transmission but also had to be given
at a dose 100 times greater than that of the wild-type virus to
produce an infection in donor animals.
58
Resistance before 2007: surveillance
Consistent with pre-treatment samples taken before the start of
clinical trials,
50 surveillance during 1996–99, before oseltamivir
and zanamivir were introduced, showed no evidence of naturally
occurring resistance.
49 Resistance remained at a low level after
the introduction of the neuraminidase inhibitors. Between 1999
and 2002, only 8 of 2287 (0.35%) inﬂuenza A and B viral isolates
showed reduced susceptibility (.10 times lower than the mean
for the virus subtype for the year in question), and none of these
was from patients known to have received a neuraminidase
inhibitor.
61 Only one of the eight isolates carried a known resist-
ance mutation (H275Y)—the others carried different variations in
the neuraminidase. Similarly, analysis of 1050 inﬂuenza virus iso-
lates from the 2000–01 and 2001–02 seasons did not identify
any isolate with any of the four ‘signature’ amino acid mutations
in neuraminidase known to confer resistance to oseltamivir or
zanamivir [at positions 119, 152, 274 or 292 (N2 numbering)].
62
More recently, the NISN reported an analysis of inﬂuenza virus
isolatesfrom74publichealthlaboratoriesinJapanduringthefour
seasons from 2003–04 to 2006–07.
63 Although oseltamivir use
in Japan is substantially higher than in any other country
(5–9 million prescriptions per season, with 5%–10% of the popu-
lationtreatedannually),resistancewasfoundinnomorethanone
of the viral subtypes tested (A/H1N1, A/H3N2 and B) in any single
season, and its incidence was low (0.3%–2.2%). Moreover, there
was no apparent increase in the incidence of resistance in
Japan, and no evidence of progressive accumulation of any resist-
ant subtype. Surveillance of seasonal inﬂuenza in 22 European
countries over the same period by the European Surveillance
Network for Vigilance against Viral Resistance (VIRGIL) also
found that ,1% of strains in each season had reduced suscepti-
bility to oseltamivir.
64 The incidence of viruses with reduced sus-
ceptibility in global surveillance of resistance mutations between
2004 and 2007 was also very low (12/3261, 0.4%),
65 although
these included a new mutation (R371K) with high levels of
resistance to both oseltamivir and zanamivir.
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Figure 2. Incidence of laboratory-conﬁrmed clinical inﬂuenza in elderly
nursing home residents who received 6 weeks of seasonal prophylaxis
with oseltamivir or placebo. Figure derived from data in Peters et al.
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JACStephenson et al.
66 evaluated the emergence of resistant
virus during treatment with the recommended oseltamivir
dosages in 64 children aged 1–12 years with inﬂuenza. In this
study, oseltamivir-resistant viruses were recovered from 3 of
11 children infected with inﬂuenza A (H1N1), 1 of 34 children
with A (H3N2) and 0 of 19 children with inﬂuenza B. No evidence
of prolonged illness was detected in children infected with
drug-resistant virus.
Resistance after 2007: surveillance
Preliminary results from analysis of 2007–08 isolates showed a
rise in the incidence of A/H1N1-H275Y viruses compared with
previous seasons (57/896 isolates, 6.4%), mostly in the USA.
65
Conﬁrming this unexpected trend, the European Inﬂuenza Sur-
veillance Scheme reported that the overall prevalence of H1N1
viruses resistant to oseltamivir was 23% (586/2533 isolates
tested),
67 while the VIRGIL network put the incidence over the
entire season at 20%, but with large differences between
countries, e.g. 68% in Norway, 10% in the UK and 1% in
Italy.
68 Importantly, the majority of circulating H1N1 viruses in
Europe remained susceptible to oseltamivir (Figure 3),
69 as was
the case in the USA. In the subsequent southern hemisphere
winter in 2008, high levels of resistant H1N1 virus were seen in
South Africa (100% of 225 isolates tested) and Australia (93%
of 76 isolates tested), although rates were lower in South
Table 4. Incidence of resistant virus and associated mutations in Roche-sponsored clinical studies of oseltamivir in naturally acquired inﬂuenza
infection
50
Roche clinical trial number
(published reference if applicable) Population Oseltamivir dose (twice daily)
Incidence of resistant virus/total number
of isolates analysed
Adolescents and adults
WV15670/WV15671 (Nicholson
et al.
15, Treanor et al.
16)
healthy adults 18–,65 years 75 mg; 150 mg 2/211 (75 mg); 2/207 (150 mg)
M76001 healthy adolescents and
adults  13 years
75 mg 0/496
WV15812 at-risk adolescents and adults
 13 years
75 mg 0/61
WV15819 at-risk elderly patients
 65 years
75 mg 0/34
WV15730 healthy adults 18–,65 years 75 mg 0/7
WV15707 at-risk elderly nursing home
residents
75 mg 0/3
JV15823 (Kashiwagi et al.
95) healthy Japanese adults
 16 years
75 mg 0/88
Children and adolescents
WV15731 healthy children 1–12 years 3 mg/kg 0/5
WV15758 (Whitley et al.
19) healthy children 1–12 years 2 mg/kg 10/183
WV15759/WV15871 at-risk asthmatic children
6–12 years
2 mg/kg 0/60
NV16871 (Johnston et al.
20) at-risk asthmatic children
6–12 years
30, 45 or 60 mg depending on
body weight and age
2/26
NV16871 (unpublished) at-risk asthmatic adolescents
13–17 years
30, 45 or 60 mg depending on
body weight and age
0/17
JV16284 (unpublished) healthy Japanese children
1–12 years
2 mg/kg 7/43
Households
WV16193 (Hayden et al.
44) healthy adults and children
 1 year
75 mg (adults); 30, 45 or 60 mg
depending on body weight
(children)
0/121 (adults); 0/147 (children)
Totals adults: 4/1228 (0.33%)
children: 19/481 (4.0%)
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70 In Australia, oseltamivir-
susceptible H3N2 and B viruses were more common.
In the 2008–09 northern hemisphere season, oseltamivir-
susceptibleH3N2virusespredominatedinEurope,despitetheper-
sistence of the oseltamivir-resistant H1N1 virus.
71 In the USA,
however, H1N1 was the predominant inﬂuenza A strain, and the
majorityof the circulating inﬂuenzaviruses were resistant to osel-
tamivir (60%).
71,72In line with this, the IDSA recommended the
use of oseltamivir or zanamivir for treatment or prophylaxis of
H3N2 strains, but zanamivir or an adamantane for H1N1; where
the subtype is unknown, combining oseltamivir with an adaman-
tanemaybeconsidered.
13 Itshouldbenoted,however,thatsince
the emergence of pandemic (H1N1) 2009 inﬂuenza, the
oseltamivir-susceptible pandemic H1N1 virus now dominates
over the seasonal H1N1 virus in many countries.
73
National and regional surveillance data have provided more
information on the emergence of A/H1N1-H275Y viruses,
showing that, in general, clinical features of infection are
similar to those of wild-type virus. Patients in the Netherlands
(from whom 28% of 119 H1N1 isolates were resistant),
74
France (366 patients with resistant and susceptible virus)
75 and
Norway (265 patients)
76 showed no differences in demographics
or outcomes (including hospitalization for the latter) compared
with persons infected with susceptible viruses. Equally, in the
USA, data from 99 oseltamivir-resistant and 182 oseltamivir-
susceptible cases from the 2007–08 season did not reveal any
signiﬁcant differences in terms of demographic characteristics,
underlying medical illness or clinical symptoms.
77 A preliminary
analysis of 1184 H1N1 isolates across the whole of Europe
from the VIRGIL database (43% of all those tested) also found
no difference in age group distribution between the resistant
and susceptible strains.
78 Notably, the Dutch, Norwegian and
American surveillance also found that continued transmission
of the mutant viruses was not selected by oseltamivir
use,
74,76,77 an observation that was supported by a
pan-European study that compared oseltamivir prescription
rates and national proportions of resistant viruses, and found
no association between the two.
79
A Danish group reported the death from pneumonia of an
8-year-old boy with A/H1N1 carrying the H275Y mutation (and
amino acid substitutions in other proteins),
80 and the death
from leukaemia of a 67-year-old Dutch patient infected with a
resistant H1N1 strain mutation (H275Y) was also recently docu-
mented.
81 Further information from the Netherlands was pro-
vided by a case series of two stem cell transplant recipients
and an elderly patient who developed inﬂuenza infection follow-
ing exposure to an index patient with community-acquired
H275Y-mutated H1N1.
82 In the latter case, transmission of
resistant virus was conﬁrmed, and the elderly patient and one
of the transplant patients died. Deaths in inﬂuenza patients are
not uncommon, and some age groups, notably very young chil-
dren and adults .65 years, have a higher mortality risk than
the general population;
83,84 the impaired immune function of
the patient with leukaemia and the stem cell transplant recipient
may have increased their risk further. New studies are under way
to assess the beneﬁt of oseltamivir treatment and prevention in
immunocompromised patients (see below).
Safety
Neuropsychiatric adverse events (NPAEs)
From the 2004–05 season, an increased incidence of NPAEs in
inﬂuenza patients taking oseltamivir was noted through post-
marketing surveillance.
85 Analysis of the Roche safety database
revealed 3051 spontaneously reported NPAEs in 2466 patients
who received oseltamivir between 1999 and 15 September
2007, during which time oseltamivir had been prescribed to
48 million people worldwide (Roche, data on ﬁle). The majority
(90.9%) of the reported NPAEs originated in Japan.
85 In both
Japan and the USA, higher crude reporting rates were seen in
children and young adolescents aged  16 years (9.9 and 1.9
events/100000 prescriptions, respectively) than adults (2.8 and
0.8 events/100000 prescriptions). NPAEs were more commonly
reported in children (2218 events in 1808 aged  16 years
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JACversus 833 in 658 adults) and generally occurred within 48 h of
the onset of inﬂuenza illness and initiation of treatment.
85
Roche conducted a comprehensive safety analysis to investi-
gate the increased reporting of NPAEs. In Phase III treatment
studies, therewas no difference in reporting rates between oselta-
mivirand placebo (both ,1%).
85 Analyses of US healthcare claims
databases showed that the risk of NPAEs in oseltamivir-treated
patients(n¼159386)wasnohigherthanforthosenotonantiviral
medication (n¼159386), while medical records in the UK General
Practice Research Database showed that the relative adjusted risk
of NPAEs in inﬂuenza patients was signiﬁcantly higher (1.75-fold)
than in the general population.
85 Further US healthcare database
analyses have been published since the Roche review and
conﬁrm these observations in both the general population aged
 1 year
86 and those aged 1–17 years
86 and 1–21 years.
87 A lit-
eraturereviewrevealedthatNPAEshavebeenreportedinJapanese
andTaiwanesechildrenwithinﬂuenzabeforeinitiationofoseltami-
vir treatment; events occurring before treatment were similar to
those occurring afterwards.
85 A similar observation was also
made in a more recent Taiwanese clinical case series.
88
The in vitro and in vivo CNS tolerability proﬁle of oseltamivir has
beenrevisitedaspartofthecomprehensivesafetyreview.Noclini-
cally relevant differences in plasma pharmacokinetics of
oseltamivir and its active metabolite oseltamivir carboxylate
(OC) were noted between Japanese and Caucasian adults
89 or
children.
90 Penetration into the CNS of both oseltamivir and OC
was low in Japanese and Caucasian adults (CSF/plasma
maximum concentration and AUC ratios of 0.03; Figures 4 and
5),
91 and the capacity for converting oseltamivir into OC in rat
and human brain was low.
85 In animal autoradiography studies,
brain/plasma radioactivity ratios were generally 20% or lower,
and animal studies showed no speciﬁc CNS/behavioural effects
after administration of doses corresponding to  100 times the
clinical dose.
85 Oseltamivir and OC did not interact with human
neuraminidase or with 155 known molecular targets in radioli-
gand binding and functional assays. A literature review of
functionalvariationsofgenesrelevanttooseltamivirpharmacoki-
netics and pharmacodynamics and simulated gene knock-out
scenarios have not identiﬁed any plausible genetic explanations
for the observed NPAEs.
85 A literature review indicated that
inﬂuenza itself may be associated with a variety of neurological
sequelae.
92 Based on this information and the ﬁndings of the
safety review, a disease-mediated pathogenesis for the observed
NPAEs appears likely. Recently published retrospective studies
have conﬁrmed a lack of association between oseltamivir and
NPAEs.
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Pooled safety data from the oseltamivir clinical treatment pro-
gramme have been reported at length previously.
93 In adults
and children, oseltamivir treatment was generally well tolerated,
with an overall incidence of adverse events similar to placebo. In
treatment studies in adults, only nausea and vomiting were
reported with a higher frequency in the oseltamivir arms, and
these events generally occurred on the ﬁrst or second day,
were mild in intensity and resolved without discontinuation.
The incidence of adverse events was similar between oseltamivir
and placebo and was similar in younger (,65 years) and elderly
adults ( 65 years).
93 Limited data in immunocompromised
patients also suggest that oseltamivir treatment is well toler-
ated.
31 In view of the known association between inﬂuenza
and deaths from cardiac disorders, a thorough review of the
available data on cardiac safety in patients exposed to oseltami-
vir was conducted.
93 No effect on QTc intervals or T wave mor-
phology was evident, and pre-clinical studies showed that
oseltamivir had no potential for effects on cardiac repolarization.
In children, vomiting and abdominal pain were the only
events that occurred more frequently with oseltamivir; generally,
these took place at the start of treatment and resolved rapidly
without leading to complications such as dehydration. In the
pooled analysis, approximately half of those  6 years had
asthma.
93 Oseltamivir had no adverse effects on pulmonary
function in these children. Similarly, in the treatment study of
asthmatic children described earlier, the overall incidence of
adverse events was similar in the oseltamivir and placebo
arms, with gastrointestinal disorders the most frequently
reported events.
20 Vomiting and abdominal pain were slightly
more frequent in the oseltamivir group than the placebo group
(15.9% versus 11.0% and 6.5% versus 4.3%, respectively),
while diarrhoea and nausea were more common with placebo
(7.3% versus 5.9% and 4.9% versus 2.4%, respectively).
General safety: prophylaxis
Oseltamivir has a well-established safety proﬁle when used as
prophylaxis for varying durations in an array of patient groups.
In the 10 day household PEP study reported by Hayden et al.,
44
the most frequently reported adverse events among contacts
receiving oseltamivir once daily as PEP were nasal congestion
(11%) and nausea (8.3%), while the incidence of vomiting was
greater among contacts receiving twice-daily treatment (9.8%
versus 4.5% in those receiving PEP). In general, adverse events
occurred more frequently in the oseltamivir PEP arm (45.4%)
than the treatment arm (30.4% of index cases, 31.4% of con-
tacts), which may reﬂect the extended duration of therapy (10
versus 5 days).
44 Six weeks of oseltamivir prophylaxis was also
well tolerated by adults
45 and elderly nursing home residents,
46
with an adverse event proﬁle similar to placebo. Oseltamivir was
also generally well tolerated in the non-randomized paediatric
seasonal prophylaxis study by Reisinger et al.
47 Over the 42 day
treatment period, 35% of participants reported adverse events,
most commonly gastrointestinal disorders, infections and respir-
atory disorders. No serious adverse events were reported.
Asinglepublishedreporthasdescribedthesafetyandtolerabil-
ity of oseltamivir as prevention in immunocompromised sub-
jects.
94 Forty-ﬁve individuals aged 11273 years who were
resident at a facility for patients undergoing HSCTreceived oselta-
mivir PEP following an inﬂuenza outbreak; this cohort was
matched with another patient group who did not receive prophy-
laxis (n¼45). Oseltamivir was well tolerated compared with con-
trols,andnodeathsoccurredthatwereattributabletooseltamivir.
Adverse events and populations of special interest
In a retrospective study of 771 evaluable Japanese infants aged
,1 year, the incidence of adverse drug reactions and adverse
events was low (3.2% and 5.3%, respectively), with diarrhoea
the most frequently reported event (Roche, data on ﬁle). No
serious adverse drug reactions were recorded. In the previously
described study of infants by Tamura et al.,
21 the only adverse
event of note in the ,1 year group was diarrhoea, which
occurred in 1 infant only (2.1%), while in the older treatment
group (aged 1–15 years) adverse events were seen in 41 children
(8.4%). No serious complications were associated with oseltami-
vir in either treatment group. In the retrospective analysis by
Skopnik and Siedler,
22 all but one of the 157 infants completed
the full 5 day course of oseltamivir therapy. Oseltamivir was gen-
erally well tolerated, apart from mild gastrointestinal side effects
that did not require medication (vomiting in 62 infants and diar-
rhoea in 34). In at least 10 cases, these symptoms were attribu-
table to concomitant gastrointestinal infections.
Ongoing studies of oseltamivir in seasonal
inﬂuenza
A prospective, age-stratiﬁed, pharmacokinetic, pharmacody-
namic and safety evaluation of oseltamivir in children aged
,24 months with conﬁrmed inﬂuenza is currently being under-
taken in collaboration with the US NIH. Additionally, Roche is
sponsoring a resistance study [the Inﬂuenza Resistance Infor-
mation Study (IRIS)] that is planned to run for at least three
inﬂuenza seasons (from 2008–09 to 2010–11) and recruit
patients from countries in the northern and southern hemi-
spheres. The study’s main objective is to assess the clinical
impact of resistance to antiviral drugs, both naturally occurring
and drug induced. To achieve this, clinical as well as virological
data on susceptible and resistant inﬂuenza infections will be col-
lected. The aim is to recruit 1200 inﬂuenza patients each year
from Europe, the USA, Asia and Australia, and to monitor clinical
and virological outcomes in treated and untreated patients with
inﬂuenza.
Conclusions
The burden of inﬂuenza in low- and high-risk groups warrants
effective countermeasures. Vaccination is central to disease pre-
vention, but limitations in terms of coverage and efﬁcacy mean
effective antiviral options are also important, especially for
those at high risk of inﬂuenza-associated complications. Oselta-
mivir is a widely used oral antiviral that is effective and well tol-
erated in a variety of low- and high-risk patient populations,
when used for the treatment and prophylaxis of inﬂuenza.
There is now a substantial body of clinical and epidemiological
evidence to show that oseltamivir therapy reduces the incidence
of potentially serious secondary complications. The issue of viral
Oseltamivir for seasonal treatment and prophylaxis of inﬂuenza
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JACresistance to oseltamivir remains important, particularly in light
of recent increases in the prevalence of resistant strains;
ongoing surveillance is essential.
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